Abstract
as obesity, type 2 diabetes (T2DM) and the metabolic syndrome sweep across the research and the clinical landscape of medical care, effective pharmacologic remedies for the treatment of obesity have become imperative. The complexities of nutrient impact on neurotransmitter and endocrine modulating chemistry have become increasingly better characterized as have the basic neurochemical pathways that mediate their effects. Food addiction has emerged as an important phenomenon that may help to explain and improve our capabilities of rendering bench lab research into impactful clinical intervention. Against this challenging backdrop of current research and study we introduce the notion that food may, itself, represent a type of drug. In this review of food as a drug, we outline some of the emerging science that argues how proteins, carbohydrates and fats operating on three basic levels of organismic functioning may constitute the most powerful drugs we have available to effectuate weight loss or weight gain over time. In addition, certain foods may not only be more addictive than others, but may actually have a direct effect on pro-inflammatory mediators that determine both metabolic dysfunction as well as overall neuropsychiatric function and well-being.
Keywords: Food addiction, Obesity, Overeating, Type 2 Diabetes (T2DM), High fructose corn syrup, Weight loss therapy, Metabolic resiliency, Cognitive therapy, Medical social networking, Group fellowship, metformin, allostatic, neurocognitive, bariac, D-Fenfluramine, rimonabant, anorexigenic, resilient, thermogenic, pharmacopeia, melanocortin, adipocyte, thiazolidinediones, opioids
Current Pharmaceutical Design
Title: Food as a Bariatric Drug
Volume: 17 Issue: 12
Author(s): Richard L. Shriner
Affiliation:
Keywords: Food addiction, Obesity, Overeating, Type 2 Diabetes (T2DM), High fructose corn syrup, Weight loss therapy, Metabolic resiliency, Cognitive therapy, Medical social networking, Group fellowship, metformin, allostatic, neurocognitive, bariac, D-Fenfluramine, rimonabant, anorexigenic, resilient, thermogenic, pharmacopeia, melanocortin, adipocyte, thiazolidinediones, opioids
Abstract: as obesity, type 2 diabetes (T2DM) and the metabolic syndrome sweep across the research and the clinical landscape of medical care, effective pharmacologic remedies for the treatment of obesity have become imperative. The complexities of nutrient impact on neurotransmitter and endocrine modulating chemistry have become increasingly better characterized as have the basic neurochemical pathways that mediate their effects. Food addiction has emerged as an important phenomenon that may help to explain and improve our capabilities of rendering bench lab research into impactful clinical intervention. Against this challenging backdrop of current research and study we introduce the notion that food may, itself, represent a type of drug. In this review of food as a drug, we outline some of the emerging science that argues how proteins, carbohydrates and fats operating on three basic levels of organismic functioning may constitute the most powerful drugs we have available to effectuate weight loss or weight gain over time. In addition, certain foods may not only be more addictive than others, but may actually have a direct effect on pro-inflammatory mediators that determine both metabolic dysfunction as well as overall neuropsychiatric function and well-being.
Export Options
About this article
Cite this article as:
L. Shriner Richard, Food as a Bariatric Drug, Current Pharmaceutical Design 2011; 17 (12) . https://dx.doi.org/10.2174/138161211795656710
DOI https://dx.doi.org/10.2174/138161211795656710 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sirtuins as Possible Drug Targets in Type 2 Diabetes
Current Drug Targets Regulatory T Cells in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery The Role of TNF and Its Family Members in Inflammation and Cancer: Lessons from Gene Deletion
Current Drug Targets - Inflammation & Allergy Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges
Current Medicinal Chemistry Role of NUCB2/nesfatin-1 in Glucose Control: Diverse Functions in Islets, Adipocytes and Brain
Current Pharmaceutical Design Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Insulin Resistance and Diabetes in HIV Infection
Recent Patents on Anti-Infective Drug Discovery Patent Selections:
Recent Patents on Biomarkers Quantitative Proteomics Reveals Changes in Transporter Protein Abundance in Liver, Kidney and Brain of Mice by Pregnancy
Drug Metabolism Letters The GSTM1 and GSTT1 Null Genotypes Increase the Risk for Type 2 Diabetes Mellitus and the Subsequent Development of Diabetic Complications: A Meta-analysis
Current Diabetes Reviews Therapeutic Targets for the Prevention of Type 1 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Maternal Sepsis 2010: Early Recognition and Aggressive Treatment with Early Goal Directed Therapy can Improve Maternal Outcomes
Current Women`s Health Reviews Current Status of Computer-Aided Drug Design for Type 2 Diabetes
Current Computer-Aided Drug Design Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Proteochemometrics for the Prediction of Binding to the MHC Proteins
Letters in Drug Design & Discovery Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters Editorial
Current Diabetes Reviews